目的 探讨采取消炎利胆胶囊联合头孢唑林钠治疗慢性胆囊炎患者的临床效果。方法 选取子长县人民医院2016年3月-2017年3月收治的慢性胆囊炎患者125例，随机分成对照组（62例）和治疗组（63例）。对照组患者静脉滴注注射用头孢唑林钠，1.0 g加入250 mL生理盐水，2次/d，连续治疗14 d。治疗组患者在对照组的基础上口服消炎利胆胶囊，3粒/次，3次/d，连续服用30 d。观察两组患者临床疗效，比较治疗前后两组患者主要临床症状积分、肝胆功能生化指标、炎性指标和不良反应情况。结果 治疗后，对照组临床总有效率为79.03%，显著低于治疗组的95.24%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者主要临床症状积分显著降低（P<0.05）；且治疗组患者各症状积分比对照组降低的更明显（P<0.05）。治疗后，两组丙氨酸氨基转移酶（ALT）、门冬氨酸转氨酶（AST）和总胆红素（TBIL）均明显降低（P<0.05）；且治疗组肝胆功能生化指标降低后水平明显优于对照组（P<0.05）。治疗后，两组患者超敏C反应蛋白（hs-CRP）、IL-6和肿瘤坏死因子-α（TNF-α）均较治疗前明显降低（P<0.05）；且治疗组各炎性指标比对照组降低的更明显（P<0.05）。治疗期间，治疗组患者不良反应发生率明显低于对照组患者，两组患者比较差异具有统计学意义（P<0.05）。结论 消炎利胆胶囊联合头孢唑林钠治疗慢性胆囊炎疗效显著，可有效改善患者的肝胆功能与体内炎性反应，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Xiaoyan Lidan Capsules combined with cefazolin sodium in treatment of chronic cholecystitis. Methods Patients (125 cases) with chronic cholecystitis in Zichang People's Hospital from March 2016 to March 2017 were randomly divided into control (62 cases) and treatment (63 cases) groups. Patients in the control group were iv administered with Cefazolin Sodium for injection, 1 g added into normal saline 250 mL, twice daily, and they were treated for 14 d. Patients in the treatment group were po administered with Xiaoyan Lidan Capsules on the basis of the control group, 3 grains/time, three times daily, and they were treated for 30 d. After treatment, the clinical efficacy was evaluated, and the main clinical symptom scores, hepatobiliary biochemical indicators, inflammatory indicators and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 79.03%, which were significantly lower than 95.24% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the main clinical symptom scores in two groups was significantly decreased (P<0.05). And these scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the ALT, AST and TBIL levels in two groups were significantly decreased (P<0.05). And the hepatobiliary biochemical indicators in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the Hs-CRP, IL-6 and TNF-α levels in two groups were significantly decreased (P<0.05). And the inflammatory indicators levels in the treatment group were significantly lower than those in the control group (P<0.05). During the treatment, the incidence of adverse reactions in the treatment was significantly lower than that in the control group, with significant difference between two groups (P<0.05). Conclusion Xiaoyan Lidan Capsules combined with cefazolin sodium has obvious curative effect in treatment of chronic cholecystitis, can improve the liver function and inflammatory reaction, which has a certain clinical application value.